Putative invasive pulmonary aspergillosis within medical wards and intensive care units: a 4-year retrospective, observational, single-centre study by Corcione, S. et al.
Vol.:(0123456789) 
Internal and Emergency Medicine 
https://doi.org/10.1007/s11739-021-02705-z
IM - ORIGINAL
Putative invasive pulmonary aspergillosis within medical wards 
and intensive care units: a 4‑year retrospective, observational, 
single‑centre study
Silvia Corcione1,2 · Tommaso Lupia1  · Stefania Raviolo1 · Giorgia Montrucchio1 · Alice Trentalange1 · 
Antonio Curtoni3 · Rossana Cavallo3 · Francesco Giuseppe De Rosa1
Received: 3 October 2020 / Accepted: 8 March 2021 
© The Author(s) 2021
Abstract
Blot and colleagues have proposed putative invasive pulmonary aspergillosis (PIPA) definitions for troublesome diagnosis 
in suspected patients outside the classical criteria of immunosuppression. We retrospectively included in the study all admit-
ted patients with an Aspergillus spp. positive culture within lower airway samples. Overall, Aspergillus spp. positivity in 
respiratory samples was 0.97 every 1000 hospital admissions (HA): 4.94 and 0.28/1000/HA, respectively, in intensive care 
units (ICUs) and medical wards (MW). 66.6% fulfilled PIPA criteria, and 33.4% were defined as colonized. 69.2% of PIPA 
diagnosis occurred in the ICU. Antifungal therapy was appropriate in 88.5% of subjects with PIPA and 37.5% of colonized, 
confirming the comparison between deads and lives. Patients with PIPA in the ICUs had more frequent COPD, sepsis or 
septic shock, acute kidney injury (AKI), needed more surgery, mechanical ventilation (MV), vasopressors, hemodialysis, 
blood or platelets transfusions. PIPA in MW had associated with a history of smoking, interstitial lung disease and inhaled 
steroid therapy. Overall mortality within 21 days was 50%: 54.2% in ICU, 36,8% in MW. Factors associated with death were 
length of hospitalization, influenza, pneumonia, liver transplant, AKI, ARDS, sepsis and septic shock. PIPA in the ICU had 
higher disease severity and needed more organ support than MW cases, despite that cases of PIPA in MW are emerging with 
trends difficult to demonstrate given the problematic diagnosis.
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Introduction
Invasive fungal infections (IFIs) are well categorized in 
hematological and severely immunosuppressed patients. 
According to the recently revised and updated definitions 
of the European Organization for Research and Treatment 
of Cancer/Mycosis Study Group (EORTC/MSG) [1], IFIs 
are classified as proven, probable or possible. Diagnosis of 
IFIs is based on the presence of a combination of classi-
cal host factors (e.g., neutropenia, hematopoietic stem cell 
transplant [HSCT], immunosuppressants or prolonged cor-
ticosteroid therapy) or recently added factors (e.g., severe 
inherited immunodeficiencies and low CD4 count), clini-
cal features and positive mycology [1]. In addition to these 
factors, low doses of corticosteroids, chronic obstructive 
pulmonary disease (COPD), liver cirrhosis, systemic con-
nective tissue diseases, influenza infection, diabetes mel-
litus and advanced solid cancer have been described as a 
favorable environment for IFIs, especially for invasive pul-
monary aspergillosis (IPA) [2, 3]. These extends this condi-
tions beyond hematological departments to primarily involve 
patients admitted to the intensive care unit (ICU) and medi-
cal wards (MWs) [2, 3]. The signs and symptoms of IFIs 
have low specificity in these settings, and most diagnostic 
tests have only been validated in neutropenic hematologic 
or severely immunocompromised patients [3, 4]. Thus, diag-
nosis is often troublesome and delayed [3, 4]. To solve this 
problem, a new definition of putative IPA (PIPA) has been 
proposed by Blot and colleagues [5] for patients who do 
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not fulfill the EORTC/MSG criteria [1]. The definition is 
based on the contemporary presence of clinical and radio-
logical criteria with risk factors in patients who have positive 
Aspergillus spp. cultures [3, 5]. This study aimed to describe 
the epidemiology, risk factors, and clinical and prognostic 
features associated with a diagnosis of PIPA in a 4-year ret-
rospective single-center analysis of hospitalized patients in 
the ICU. Additionally, the study extended the analysis to 
MW settings.
Methods
A retrospective, observational, monocentric study was 
conducted. The study included all patients with a positive 
Aspergillus spp. culture in lower airway samples obtained 
through bronchoalveolar lavage (BAL) or broncho-aspirate 
(BA) who were admitted between 01 January, 2012 and 31 
December, 2016 to the MWs and ICU at Città Della Salute 
e Della Scienza di Torino–Presidio Molinette. Patients with 
a previous history of onco-hematological diseases (iron 
deficiency anemia, hemophilia, sickle cell disease, thalas-
semia, leukemias and lymphomas) or a history of IPA were 
excluded. Each patient’s demographics and clinical and 
microbiological data were collected from electronic medi-
cal records and expressed as medians with interquartile 
ranges (IQRs). The incidence of positive culture was cal-
culated on the thousandth hospital admission (HA). Signs 
and symptoms compatible with the clinical algorithm by 
Blot et al. [5] were reported along with the microbiological 
data. Positive Aspergillus spp. culture, blood galactomannan 
(GM) test, GM obtained through BAL or BA samples and a 
direct microscopic exam or polymerase chain reaction (PCR) 
for Aspergillus spp test positivity were collected. Mortality 
was evaluated 21 days after direct microbiological diagnosis 
(e.g., positive Aspergillus spp. culture, direct microscopic 
exam) or indirect diagnosis (e.g., GM). The study population 
was divided into three groups according to Blot et al. [5]. 
The first group included patients with a proven diagnosis 
of IPA according to the EORTC/MSG [1] definition (i.e., 
Aspergillus spp. positivity on microscopic analysis or cul-
tures). The second group included patients with a diagnosis 
of PIPA who met all four following criteria:
1. Aspergillus-positive lower respiratory tract specimen 
culture (entry criterion).
2. Compatible signs and symptoms, including at least one 
of the following:
(a) Fever refractory to at least 3 days of appropriate 
antibiotic therapy.
(b) Recrudescent fever after a period of defervescence 
of at least 48 h, while still on antibiotics and with-
out other apparent cause.




(g) Worsening respiratory insufficiency despite appro-
priate antibiotic therapy and ventilatory support.
3. Abnormal medical imaging by portable chest X-ray or 
CT scan of the lungs.
4. Either IVa or IVb.
(a) IVa host risk factors (one of the following con-
ditions): neutropenia (absolute neutrophil count, 
500/mm3) preceding or at the time of ICU admis-
sion, underlying hematological or oncological 
malignancy treated with cytotoxic agents, glu-
cocorticoid treatment (prednisone equivalent, 
20 mg/day) and congenital or acquired immuno-
deficiency.
(b) IVb semiquantitative Aspergillus-positive culture 
of BAL fluid (+ or ++) without bacterial growth 
together with a positive cytological smear show-
ing branching hyphae
Group three included patients with Aspergillus spp. res-
piratory tract colonization (when ≥ 1 criterion necessary for 
a diagnosis of PIPA was not met). Appropriate antifungal 
therapy at the time of microbiological positivity was ret-
rospectively evaluated according to the currently available 
international guidelines from the Infectious Diseases Society 
of America (IDSA) and European Society of Clinical Micro-
biology and Infectious Diseases (ESCMID). Data were col-
lected in an Excel spreadsheet and analysed the Statistical 
Package for the Social Sciences (SPSS) 18.0. continuous 
variables were reported as mean (standard deviation) or 
median (IQR). categorical variables were reported as abso-
lute numbers (percentages). Non-parametric tests (Wil-
coxon, Mann–Whitney, Chi-square and Fisher’s exact tests) 
were used for univariate analyses. For categorical variables, 
Chi-square and Fisher’s tests were used depending on the 
distribution of the contingency tables. Non-parametric tests 
(Wilcoxon and Mann–Whitney) were used for continuous 
variables, and Chi-square and Fisher’s tests were used for 
categorical variables. The significance level was set at 0.05 
to judge the strength of evidence for hypothesis testing. Fac-
tors presenting a significant level in the univariate analyses 
were included in the multivariate analyses (log regression) 
to assess for risk factors of death outcome.
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Results
During the study period, 80,570 patients were admitted to 
the ICUs and MWs. Overall, Aspergillus spp. positivity 
in the lower airway cultures (e.g., BAL or BA) was 0.97 
for every 1000 HA distributed as follows: 4.94/1000 in 
the ICUs and 0.28/1000 in the MWs. Of these patients, 76 
(0.09%) fulfilled the criteria to be included in the study. 
The median age was 66.5 years old (range 58–77 years; 
65.4%, ≥ 60  years), and the patients were mostly men 
(75.6% male vs. 24.4% female). The median hospital 
length of stay (LOS) was 32 days (range 17.75.59 days), 
and the patients were hospitalized more frequently in the 
ICUs (76.3%) than in the MWs (23.7%). The algorithm 
for PIPA by Blot et al. [5] was applied to the patients. Of 
the 76 individuals, 52 (68.4%) had a diagnosis of PIPA. 
Of these patients diagnosed with PIPA, 69.2% were hos-
pitalized in the ICU, and 30.8% were hospitalized in the 
MWs. The remaining 24 patients did not fulfill the PIPA 
criteria, so microbiological positivity was considered as 
lower respiratory tract colonization in these patients. The 
main characteristics of the entire population are shown in 
Table 1. Regarding comorbidities, the majority of patients 
had cardiovascular disease (73.1%), acute kidney injury 
(51.3%) or diabetes (42.3%). Other relevant comorbidities 
were COPD (42.3%) or a history of malignancy (34.6%); 
within the first group, 51.5% of the patients were undergo-
ing daily chronic steroid inhalation therapy at home. At 
the time of microbiological positivity, 83.3% needed 
O2 therapy, 73.1% needed mechanical ventilation sup-
port, 64.1% needed hemodynamic and vasopressor sup-
port, 28.1% needed hemodialysis, and 96.2% had con-
comitant antibiotic therapy. Serum GM was positive in 
20.9% of patients, with a median GM value of 1.96 ng/
mL (0.775–4.55 ng/mL, normal value < 0.5 ng/mL). How-
ever, a GM BAL/BA test was not performed in 17.8% of 
adults. GM on BAL or BA was positive in 98.2% of the 
tests, with a median value of 5.05 ng/mL (4.07–6.4 ng/
mL; normal value < 0.5 ng/mL). In the cultures, A. fumiga-
tus was the species most frequently isolated (72.9%), fol-
lowed by A. terreus, A. flavus and A. niger. Additionally, 
7 (8.9%) adults had double species isolation during hos-
pitalization. Furthermore, Aspergillus spp. isolation had 
some seasonal fluctuations and was found more often in 
winter (46.2%) and spring (21.8%). Of the patients, 73.1% 
were treated with an appropriate antifungal therapy at 
the moment of microbiological positivity. The majority 
(89.5%) were treated with amphotericin B or voricona-
zole monotherapy (42.1% vs. 36.8%, respectively), while 
the remaining patients were treated with caspofungin or 
posaconazole monotherapy or combination therapy. A uni-
variate analysis was performed to assess the differences 
between patients with a diagnosis of PIPA and those colo-
nized by Aspergillus spp. in both the ICUs and MWs. In 
patients from the ICUs, a diagnosis of PIPA was associ-
ated with more oral or intravenous steroid therapy during 
hospitalization, history of metastatic solid organ cancer, 
sepsis, features of pneumonia on X-rays or radiological 
abnormalities (Table 1). Furthermore, patients with PIPA 
in the ICUs were more frequently treated with antifun-
gal therapy compared to colonized patients (p < 0.0001) 
and were treated before microbiologic results more often 
(p = 0.03). Additionally, ICU-infected patients underwent 
hemodialysis more commonly than colonized patients 
and had more respiratory insufficiency and worsening of 
respiratory insufficiency despite antibiotic therapy and 
adequate mechanical ventilation (Table 1). Subsequently, 
a univariate analysis (Table 1) was performed to assess the 
differences between patients with PIPA in the ICUs and 
MWs. Patients with PIPA in the ICUs presented more fre-
quently with COPD, sepsis, septic shock and acute kidney 
failure. Moreover, ICU subjects needed surgical interven-
tion or support therapies, such as mechanical ventilation, 
vasopressors, hemodialysis and blood or platelet transfu-
sions, more often than patients in the MWs. Patients in 
the MWs were more likely to be smokers, had interstitial 
lung disease and had undergone chronic inhaled steroid 
therapy (Table 1). The estimation of mortality at day 21 
was assessed from the microbiological positivity, and 
the overall mortality within 21 days was 51.3% (39 sub-
jects). The mortality in the ICU was 82%, as opposed to 
17.9% in MW patients (p = 0.622). 37 patients (49.7%) 
survived: 25.3% went back home, 7.2% were transferred to 
another hospital, and 16.2% went to other facilities. Anti-
fungal treatment was administered to 81.5% of the non-
survivor patients diagnosed with PIPA and in 27.3% of the 
colonized dead patients. Characteristics in the univariate 
analysis (Table 2) associated with not survival were as fol-
lows: duration of hospitalization (longer in the live popula-
tion, p = 0.006), influenza diagnosis (p = 0.048), possible 
pneumonia on radiological exams (p = 0.042), liver trans-
plant (p = 0.048), acute kidney failure (p < 0.0001), acute 
respiratory distress syndrome (ARDS) (p = 0.019), sepsis 
(p < 0.0001), septic shock (p < 0.0001) and worsening of 
respiratory insufficiency in spite of mechanical ventila-
tion (p = 0.003). Immunosuppressive drugs were associ-
ated with a lower risk of death (p = 0.002). According to 
the Blot et al. criteria, antifungal therapy was appropriate 
in 88.5% of patients with a diagnosis of PIPA and 37.5% 
of colonized patients, with a statistically significant differ-
ence in the univariate analysis (p < 0.0001). This associa-
tion was confirmed after comparing non-survivor patients 
with alive ones (p = 0.001). Multivariate regression analy-
sis (Tables 3, 4) was performed for patients hospitalized 
in the ICU. The factors associated with PIPA included 
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Table 1  Main characteristics of the study population
ICU (n = 58) p value MW (n = 18) p value p value
ICU vs. MW
PIPA (n = 36) Colonization (n = 22) PIPA (n = 16) Colonization (n = 2)
n median (IRQ) n median (IRQ) n median (IRQ) n median (IRQ)
Demographic variables
 Gender (male) 28 17 0.964 12 2 1 1
 Age 66.5 (58–75.75) 71 (58–79.25) 0.475 64.5 (59.25–74.25) 78 (77–78) 0.209 0.945
 LOS 37.5 (19.5–68.5) 32 (17.75–53.5) 0.553 25 (14.5–42.25) 41.5 (28–41.5) 0.399 0.730
 LOS from microbiologi-
cal diagnosis
11.5 (6–21.75) 6 (1.75–21.5) 0.328 10.5 (3.25–17) 16.5 (13–16.5) 0.327 0.493
Comorbidities and risk factors
 Previous antibiotic treat-
ment
32 16 0.156 15 2 1 1
 Cardiovascular diseases 28 15 0.418 12 2 0.490 1
 Pneumonia 19 4 0.013 12 2 1 0.220
 COPD 12 10 0.356 11 0 0.137 0.018
 ILD 3 4 0.409 5 0 1 0.035
 Pancreatitis 4 2 1 1 0 1 1
 AKI 25 10 0.070 5 0 1 0.010
 CKD 11 3 0.209 5 2 1 0.960
 DM 12 9 0.560 5 2 0.137 0.882
 Cirrhosis 6 4 1 4 1 0.490 0.475
 Smoke
  Present 4 7 0.069 3 0 0.171 0.662
  Former 7 1 8 0 0.025
 SOT
  Lung 0 1 0.379 5 0 1 0.002
  Kidney 3 1 1 1 0 1 1
  Liver 5 2 0.698 0 0 – 0.308
 Malignancy
  Primitive 6 8 0.089 0 1 0.111 0.083
  Metastatic 9 0 0.010 3 0 1 0.733
 Influenza co-infection 4 2 1 1 0 1 1
 Steroids > 60 days 
(> 1 mg/kg/d)
4 1 0.387 5 0 1 0.113
 Steroids > 21 days 
(0.3 mg/kg/d)
7 1 0.139 7 0 0.497 0.094
 Steroids during hospitali-
zation
28 4 0.000 13 0 0.235 1
 Chronic steroid inhaler 7 4 1 9 0 0.471 0.008
 CT for malignancy 5 0 0.145 4 0 1 0.431
 Neutropenia (< 500 cell/
mm3)
2 1 1 0 0 – 1
 Immunosuppressive 
treatments
7 3 0.727 6 0 0.529 0.184
 HIV or inherited immu-
nodeficiency
2 0 0.521 0 0 – 1
 ARDS 10 3 0.332 1 0 1 0.140
 Sepsis 30 13 0.041 5 1 1 0.000
 Septic shock 27 11 0.052 1 1 0.216 0.000
 Prior TB 1 0 1 1 0 1 0.525
 No major risk factors 24 18 0.243 7 2 0.471 0.120
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steroid therapy (regardless of dosage) and absence of anti-
fungal therapy (Table 3). Multivariate regression analy-
sis for prognostic mortality factors showed (Table 4) that 
acute kidney failure (OR: 9.139; confidence interval, CI 
2.892–28.878; p = 0.0001) and worsening of respiratory 
insufficiency (OR: 4.159; CI 1.153–15.000; p = 0.029) 
despite mechanical ventilation and antibiotic therapy were 
tied with higher mortality. In contrast, liver transplants had 
a protective effect (OR: 0.066 CI 0.005–0.812; p = 0.034].
Discussion
Recently, IPA has been described in apparently immu-
nocompetent patients, and thus a new at-risk group has 
been defined, notably outside hematological wards [2–5]. 
However, definite diagnosis is problematic in every popu-
lation at risk of IPA, because it requires a lung biopsy 
demonstrating invasive growth and positive culture, which 
Table 1  (continued)
ICU (n = 58) p value MW (n = 18) p value p value
ICU vs. MW
PIPA (n = 36) Colonization (n = 22) PIPA (n = 16) Colonization (n = 2)
n median (IRQ) n median (IRQ) n median (IRQ) n median (IRQ)
Therapies
 Antifungal 30 7 0.000 16 2 – 0.160
 Switch (from antifungal 
to prophylaxis)
6 0 0.569 7 1 1 0.076
 Prophylaxis 21 6 0.030 6 2 0.183 0.165
Symptoms
 Dyspnoea 14 6 0.366 8 2 0.477 0.454
 Fever 12 2 0.057 4 1 0.490 0.747
 Recurrent fever 9 4 0.747 5 0 1 0.639
 Pleurodynia 1 0 1 1 0 1 0.525
 Pleuric rub 6 3 1 3 1 0.405 1
 Hemopptysis 0 1 0.379 2 0 1 0.090
 Respiratory failure 18 4 0.025 1 0 1 0.004
Imaging 36 13 0.000 16 2 – –
 Typical for IPA 11 0 0.275 4 1 0.593 0.890
Support therapies
 Oxygen 31 21 0.392 11 1 1 0.143
 Mechanical ventilation 34 21 1 1 0 1 0.000
 Vasopressors 30 16 0.333 3 0 1 0.000
 Hemodyalisis 16 3 0.021 2 0 1 0.031
 Blood transfusion 33 17 0.238 5 0 1 0.000
 Platelets transfusion 9 8 0.356 0 0 – 0.043
 Surgery 28 12 0.063 1 0 1 0.000
 Antibiotics 35 21 1 15 2 1 0.525
Microbiology
 GM (serum) 3/22 0/7 0.557 4/11 0/1 1 0.186
 GM BAL/BA 32/32 6/6 – 13/13 2/2 – –
 Aspergillus DNA 12/18 2/4 0.602 8/9 2/0 1 0.363
LOS lenght of stay, GM galattomannan, ARDS acute respiratory distress syndrome, BAL bronchoalveolar lavage, BA broncho-aspirate, ICU 
intensive care unit, MW medical ward, COPD chronic obstructive pulmonary disease, ILD interstitial lung disease, DM diabete mellitus, CKD 
chronic kidney disease, AKI acute kidney injury, SOT solid organ transplant
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Table 2  Characteristics of the 
study population in univariate 
analysis
Survivors (n = 39)
n median (IRQ)




 Males 28 31 0.429
 Age 63 (57–72) 71 (59–78) 0.066
 LOS 44 (18–70) 28 (16–37) 0.006
 LOS from microbiological diagnosis 9 (2–17) 13(6–13) 0.107
 ICU 27 32 0.622
 MW 12 7
Comorbidities
 Previous antibiotics 32 35 0.329
 Cardiovascular diseases 31 26 0.202
 Pneumonia 14 24 0.042
 COPD 17 16 0.819
 ILD 5 7 0.530
 Pancreatitis 4 3 1
 AKI 11 30 0.000
 CKD 8 13 0.202
 DM 14 14 1
 Cirrhosis 9 6 0.389
 Smoke
  Actual 6 8 0.765
  Former 9 7
 SOT
  Lung 5 1 0.200
  Kidney 5 0 0.055
  Liver 6 1 0.048
 Malignancy
  Solid 7 8 0.774
  Metastatic 8 4 0.347
 Influenza co-infection 1 6 0.048
 Steroids > 60 days (> 1 mg/kg/day prednisone) 6 4 0.737
 Steroids > 21 days (0.3 mg/kg/die prednisone) 8 8 1
 Steroids 23 23 0.890
 Chronica inhaled steroids 12 8 0.300
 Malignancy during chemotherapy 6 3 0.288
 Neutropenia (< 500 cell/mm3) 2 1 1
 Immunosuppressive therapies 14 2 0.001
 HIV/AIDS 1 1 1
 ARDS 3 12 0.019
 Sepsis 14 36 0.000
 Septic shock 8 33 0.000
 Previous lung tubercolosis 2 1 1
 No major risk factors 22 30 0.055
Therapy
 Antifungal 31 26 0.202
 Switch 10 4 0.139
 Antifungal prophylaxis 16 19 0.495
Symptoms
 Dispnoea 12 19 0.105
 Fever 8 12 0.300
 Recurrent fever 8 11 0.429
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is often hazardous due to the underlying conditions of the 
patients. Additionally, the diagnosis of probable or possi-
ble IPA according to EORTC/MSG [1] requires an immu-
nocompromised host, which excludes the vast majority of 
the ICU and MW population [2–5]. This study reported 
a noticeable incidence of Aspergillus spp. positivity on 
lower airway cultures in the ICU population (4.94/1000 
HA) over 4 years. The incidence is particularly notice-
able when compared to longer studies in the same set-
ting, such as the 14-year French retrospective study by 
Lugosi et al. [6]. They examined 11,992 patients admitted 
to ICUs and found that 9.08/1000 HA had Aspergillus spp. 
positivity in the lower airway cultures. Moreover, in an 
18-month surveillance program involving 18 Italian ICUs, 
the incidence of IPA was 2.3/1000 HA [7], although IPA 
has been considered a rare condition among critically ill 
patients, but with a deadly mortality between 60 and 90% 
[8, 9]. Furthermore, data on overall positivity in MWs are 
substantially lacking in the literature. Russo et al. [10] 
reported clinical features from 1351 subjects extrapolated 
during a 14-month period of infectious disease consulta-
tion in a tertiary care hospital in Italy. They found 14 cases 
of proven or probable invasive aspergillosis enrolled in 
medical and surgical wards. In the present analysis, the 
Table 2  (continued) Survivors (n = 39)
n median (IRQ)
Deceased (n = 39)
n median (IRQ)
p value
 Pleurodynia 1 1 1
 Pleuric rub 5 8 0.362
 Hemottysis 3 1 0.615
 Acute respiratory failure 6 18 0.003
Imaging 33 36 0.288
 Typical 7 10 0.849
Supportive therapies
 Oxygen 29 36 0.0.65
 Mechanical ventilation 24 33 0.040
 Vasopressors 17 33 0.000
 Hemodialysis 6 16 0.012
 Blood transfusion 23 32 0.025
 Platelets transfusion 5 13 0.032
 Surgery 22 20 0.650
 Antibiotics 37 38 0.556
Microbiology
 GM serum 4 5 0.721
 GM BAL/BA 26 28 0.491
 Aspergillus DNA 14 10 0.146
LOS lenght of stay, GM galattomannan, ARDS acute respiratory distress syndrome, BAL bronchoalveolar 
lavage, BA broncho-aspirate, ICU intensive care unit, MW medical ward, COPD chronic obstructive pul-
monary disease, ILD interstitial lung disease, DM diabete mellitus, CKD chronic kidney disease, AKI acute 
kidney injury, SOT solid organ transplant
Table 3  Risk factors for putative invasive pulmonary aspergillosis in 
multivariate analysis
aOR adjusted odd ratio, CI confidence interval
p value a OR 95% CI
Inferior Superior
Steroids 0.001 12.950 2.990 56.086
Worsening of respiratory failure 0.342 2.310 0.411 12.989
Sepsis 0.419 2.014 0.368 11.013
Lack of antifungal therapy 0.004 10.430 2.123 51.256
Hemodialysis 0.374 0.414 0.059 2.888
Table 4  Characteristics associated with 21-day mortality in multivar-
iate analysis
aOR adjusted Odd ratio, CI interval of confidence
p value a OR 95% CI
Inferior Superior
Acute kidney failure 0.000 9.139 2.892 28.878
Worsening of respiratory failure 0.029 4.159 1.153 15.000
Liver transplant 0.034 0.066 0.005 0.812
Influenza co-infection 0.206 4.751 0.425 53.160
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incidence of lower respiratory tract positivity for Asper-
gillus spp. among MWs was reported as 0.28/1000 HA. 
Within this group, 16 patients fulfilled the criteria for 
PIPA by Blot et al. [5]. Contrary to the case study by 
Russo et al. [10] that observed about 70% of PIPA cases 
in non-ICU wards, the present study described PIPA in 
just 30.8% of MWs adults with MWs. This discrepancy 
may have been related to a higher immunosuppressed MW 
population in the mentioned study [10] (e.g., high rate of 
malignancies, frequent cancer chemotherapies) and dif-
ferent diagnostic criteria. Advanced age and the predomi-
nance of males in the present study were comparable to 
the literature in this field [2, 5, 6, 10]; this predominance 
of older men may be related to the higher incidence of 
comorbidities with PIPA in the aged population, notably 
chronic lung diseases, malignancies and chronic liver dis-
eases. According to Matthaiou et al. [11], elderly patients 
were more likely to be diagnosed with PIPA than proven 
or possible IPA, due to less diagnostic radiological find-
ings concurring with a delayed diagnosis. Cardiovascu-
lar diseases (73.1%) and diabetes (42.3%) were the two 
most frequent comorbidities in this population, and the 
same distribution of underlying diseases (13.0% and 7.8%, 
respectively) was found in the study by Blot et al. [5], 
although at lower rates. A high prevalence of chronic lung 
diseases (42.3%) was found in this study, and this dis-
ease was more frequent among patients with PIPA in the 
MWs. Indeed, acute exacerbations in COPD were a cause 
of frequent admission to the MWs and ICUs. In an obser-
vational multicenter study of 563 critically ill patients 
with PIPA or Aspergillus spp. colonization, COPD was 
the most frequent underlying condition, involving 31% of 
adults [12]. Delsuc [13] and colleagues have described in 
a cohort of 677 COPD subjects admitted to the ICU that 
PIPA was a strong death predictor in critically ill patients; 
therefore, the use of corticosteroids and antibiotics before 
ICU admission was a risk factor for the development of 
PIPA. Moreover, acute kidney injury (AKI) and chronic 
kidney disease are underreported in most other studies. 
The present study found that AKI resulted in a mortality 
risk factor. Nevertheless, higher organ support was associ-
ated with more PIPA diagnoses, notably in the ICU set-
ting, than reported by other authors [5–9]. In the present 
study, MW patients included more past or former smok-
ers, interstitial lung diseases and chronic inhaled steroid 
therapies than ICU patients. Regarding the association 
between smoking and IFIs, Pourbaix et al. [10, 14] found 
an increased risk of fungal infections among smokers and 
recommended the implementation of smoking cessation 
strategies, especially in high-risk groups, such as HIV or 
hematological patients. However, ICU and MW patients 
were not included in their discussion. A. fumigatus was the 
most isolated species, followed by A. terreus. A. terreus 
has not been discussed frequently in the literature, except 
in some specific geographic areas [11, 15, 16]. This is of 
particular importance for therapy choice since A. terreus 
is resistant to amphotericin B, a first-choice therapy in 
invasive aspergillosis, along with voriconazole and isavu-
conazole [11, 15, 16]. The mortality of the current study’s 
population was similar to neutropenic and non-neutropenic 
populations affected by aspergillosis. No difference in 
mortality was found between patients with PIPA and colo-
nized patients. This observation was recently confirmed by 
Paiva et al. among ICUs in which patients with putative/
proven IPA were more likely to receive antifungal thera-
pies than colonized patients (78.7% vs. 25.5).. As shown 
in the present study, Aspergillus isolation must not always 
be considered as simple colonization or contamination in 
immunocompromised patients, as IPA can also occur in 
patients who lack classical risk factors, like neutropenia 
or therapies with immunosuppressant drugs. The mortality 
for IPA in non-neutropenic is comparable to neutropenic 
patients, and high comorbidities in the MWs, along with 
the ICU population as reported in other studies [17, 18] 
and must be screened in the absence of other compatible 
diagnoses for IPA.
There are several limitations to this study. First, this is a 
single-centre study. Our patient population may not accu-
rately reflect the general demographics of Italy. Second, 
there are some missing data, such as information regarding 
APS or APACHE score for ICU patients and in mortality 
analysis and GOLD classification in COPD patients. Third, 
the low numerosity of the sample included in our study.
In conclusion, in our study, MW patients primarily suf-
fered from underlying respiratory diseases such as pneu-
monia and COPD, whereas ICU patients had a wider range 
of comorbid conditions, higher disease severity and needed 
more organ support.
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